FDA Inspections

FDA Inspected Centeral and Eastern European Regions

Russia Central Europe

FDA: Inspections and findings

NAI	No Action Indicated	No objectionable conditions or practices were found during the inspection
VAI	Voluntary Action Indicated	Objectionable conditions were found but the problems do not justify further regulatory action. Any corrective action is left to the investigator to take voluntarily.
OAI	Official Action Indicated	Objectionable conditions were found and regulatory and/or administrative sanctions by FDA are indicated.

Russia: competitive advantages

FDA inspections Central and Eastern Europe

ICH GCP Compliance in Russia: NAI

The U.S. Food and Drug Administration found no evidence of poor GCP compliance during inspections in Russia or other emerging clinical research sites.